Telormedix is a clinical-stage biopharmaceutical company focused on targeted modulation of the innate immune system through TLR7 agonists to treat cancer and autoimmune/inflammatory diseases. Its lead product, TMX-101, is in a Phase I/II clinical trial for Non-Muscle Invasive Bladder Cancer (NMIBC). The company is also developing two TLR7-targeted molecules, TMX-201 and TMX-202, as vaccine adjuvants; TMX-202 has shown significant preclinical results and was selected for preclinical study as a topical treatment for skin cancers. Telormedix plans to use recently raised funds to further advance its product candidates through preclinical and clinical trials and to support development of additional molecules. The company was founded in October 2007 and is located in Switzerland. Management states the financing from existing investors will allow it to reach next development milestones.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2012